SAT-LB081 Growth Hormone and Prolactin Secreting Plurihormonal Pituitary Adenomas, Experience of a National Health Institute in Mexico

Introduction Pituitary adenomas represent approximately 15% of all intracranial neoplasms. Those with the ability to produce more than one hormone are called plurihormonal pituitary adenomas. They are divided into monomorphic, single cell type may produces two or more hormones, and plurimorphic, different cell types may produce multiple hormones. Materials and methods We performed a retrospective review of all patients diagnosed with hyperprolactinemia and acromegaly secondary to pituitary adenoma during the period 2004-2018. Then, we identified 10 patients with high serum levels of PRL and IGF-1. Six of these patients were excluded due to hyperprolactinemia secondary to pituitary stalk compression. We collected clinical, biochemical and medical imaging information. We compared the clinical and biochemical characteristics before and after treatment. Results We identified 4 female patients with GH/PRL-secreting plurihormonal pituitary adenoma. The average age at diagnosis was 25 years-old (20-32). We documented high serum levels of IGF-1 with average of 818 ng/mL (474-1340 ng/ml) and PRL with average of 185.62 ng/mL (120.95 to 280.13 ng/ml). On admission, a pituitary Magnetic Resonance Imaging (MRI) revealed macroadenoma, with mean diameter 23.5 mm (18-32 mm). All patients were prescribed cabergoline in average dose of 0.75 mg (0.5-1 mg) per week. Half of the patients had their IGF-1 ng/mL plasma level normalized. PRL ng/ml plasma levels were decreased in all patients. In their last pituitary MRI, the size of the macroadenoma decreased in all patients (8.1mm), with a mean diameter of 15.4 mm. Conclusion We consider that the primary management of the plurihormonal pituitary adenomas is the use of dopamine receptor agonists; in case there is not a clinical or biochemical control of the disease, we suggest to evaluate using additional therapy. Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.